t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells.

t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells.
复制标题

DOI:
10.1371/journal.pone.0132267
复制
发表时间:
2015
期刊:
影响因子:
3.7
通讯作者:
Kane SE
Kane SE
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Denny EC;Kane SE

文献摘要

参考文献

被引文献

相似文献

Trastuzumab has led to improved survival rates of HER2+ breast cancer patients. However, acquired resistance remains a problem in the majority of cases. t-Darpp is over-expressed in trastuzumab-resistant cell lines and its over-expression is sufficient for conferring the resistance phenotype. Although its mechanism of action is unknown, t-Darpp has been shown to increase cellular proliferation and inhibit apoptosis. We have reported that trastuzumab-resistant BT.HerR cells that over-express endogenous t-Darpp are sensitized to EGFR inhibition in the presence (but not the absence) of trastuzumab. The purpose of the current study was to determine if t-Darpp might modulate sensitivity to EGFR inhibitors in trastuzumab-resistant cells. Using EGFR tyrosine kinase inhibitors AG1478, gefitinib and erlotinib, we found that trastuzumab-resistant SK.HerR cells were sensitized to EGFR inhibition, compared to SK-Br-3 controls, even in the absence of trastuzumab. t-Darpp knock-down in SK.HerR cells reversed their sensitivity to EGFR inhibition. Increased EGFR sensitivity was also noted in SK.tDp cells that stably over-express t-Darpp. High levels of synergy between trastuzumab and the EGFR inhibitors were observed in all cell lines with high t-Darpp expression. These cells also demonstrated more robust activation of EGFR signaling and showed greater EGFR stability than parental cells. The T75A phosphorylation mutant of t-Darpp did not confer sensitivity to EGFR inhibition nor activation of EGFR signaling. The over-expression of t-Darpp might facilitate enhanced EGFR signaling as part of the trastuzumab resistance phenotype. This study suggests that the presence of t-Darpp in HER2+ cancers might predict the enhanced response to dual HER2/EGFR targeting.
DOI: 10.1371/journal.pone.0006220
发表时间: 2009-07-13
期刊: PloS one
影响因子: 3.7
作者:
Gu L;Waliany S;Kane SE
通讯作者: Kane SE
DOI: 10.1186/1476-4598-9-240
发表时间: 2010-09-13
期刊: MOLECULAR CANCER
影响因子: 37.3
作者:
Vangamudi, Bhavatarini;Peng, Dun-Fa;Belkhiri, Abbes
通讯作者: Belkhiri, Abbes
DOI: 10.1200/jco.2005.09.055
发表时间: 2005-02-20
影响因子: 45.3
作者:
DiGiovanna, MP;Stern, DF;Thor, AD
通讯作者: Thor, AD
DOI: 10.1158/0008-5472.can-12-1119
发表时间: 2012-09-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Hong, Jun;Katsha, Ahmed;El-Rifai, Wael
通讯作者: El-Rifai, Wael
DOI: 10.1002/path.1003
发表时间: 2002-01-01
影响因子: 7.3
作者:
Suo, Z;Risberg, B;Nesland, JM
通讯作者: Nesland, JM